Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Phase 1 Completed 50 enrolled GlaxoSmithKline

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will test the safety of treating colorectal cancer with a combination of drugs. The current standard treatments of FOLFOX6 or CapeOx will be give in combination with the GSK investigational drug pazopanib.

Timeline

Start: 2006-10-20
Primary completion: 2009-08-14
Completion: 2009-08-14

Publications

Brady J, Corrie P, Chau I, Digumarti R, Adams LM, Botbyl J, Laubscher KH, Midgley RS, Mallath M. An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. Invest New Drugs. 2013 Oct;31(5):1228-35. doi: 10.1007/s10637-013-9938-7. Epub 2013 Feb 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pazopanib	Small molecule	800 mg	Oral
Background	Capecitabine	Small molecule	850 mg/m2	Oral
Background	Capecitabine	Small molecule	1000 mg/m2	Oral
Background	Leucovorin	Small molecule	400 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	100 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Background	fluorouracil	Small molecule	400 mg/m2	Intravenous
Background	fluorouracil	Small molecule	2400 mg/m2	Intravenous
Background	fluorouracil	Small molecule	3000 mg/m2	Intravenous

Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Summary

Timeline

Publications

Drugs

Indications